You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Altis Labs raises US$25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to enhance AI models for clinical development.
PRIVATESep 17, 2026•about 3 hours ago
Amount Raised
$25 Million
Round Type
Series A
Toronto
Investors
Lumira VenturesFusion FundBenchstrengthInnovation EndeavorsQiming Venture Partners UsaOrbi Med
Description
Altis Labs, an AI endpoint company, has closed a US$25 million Series A financing round. The funding was co-led by OrbiMed and Qiming Venture Partners USA, with additional support from various investors. The capital will be utilized to expand Altis’ AI models across cancer types and scale commercial deployment. This investment aims to accelerate clinical development in the healthcare sector.
Company Information
Company
Altis Labs
Location
Toronto, Ontario, Canada
About
Altis Labs is the AI-powered computational imaging company advancing precision medicine.
We believe that medical imaging, making up 90% of all healthcare data, is the richest source of clinical insight but is vastly underutilized due to 40-year-old reductionist interpretation guidelines.
Trained on the world's largest proprietary cancer imaging database, our deep learning algorithms help quantify treatment effect beyond simplistic and discordant tumor size measurements.
Leading biopharmaceutical companies use our AI-powered imaging biomarker platform, Nota, to analyze clinical trial imaging data in a more meaningful way, allowing them to accelerate and de-risk all stages of clinical development.
Based in Toronto, a city recognized for its deep learning research and renowned medical institutions, our multi-disciplinary team is on a mission to guide personalized treatment and help patients get access to the most effective therapies sooner.
Don't miss Altis Labs's next move
Get an email the moment Altis Labs raises, hires an exec, or expands, usually minutes after it happens.
Toronto